nodes	percent_of_prediction	percent_of_DWPC	metapath
Nabilone—Dronabinol—CYP3A4—bone cancer	0.0485	1	CrCbGaD
Nabilone—CNR1—GPCRs, Other—GRM1—bone cancer	0.00505	0.0848	CbGpPWpGaD
Nabilone—Abnormal dreams—Doxorubicin—bone cancer	0.00479	0.00537	CcSEcCtD
Nabilone—Eye disorder—Cisplatin—bone cancer	0.00479	0.00537	CcSEcCtD
Nabilone—Coma—Epirubicin—bone cancer	0.00479	0.00537	CcSEcCtD
Nabilone—Tinnitus—Cisplatin—bone cancer	0.00478	0.00535	CcSEcCtD
Nabilone—Flushing—Cisplatin—bone cancer	0.00475	0.00533	CcSEcCtD
Nabilone—Photosensitivity—Methotrexate—bone cancer	0.00463	0.00519	CcSEcCtD
Nabilone—Arrhythmia—Cisplatin—bone cancer	0.00458	0.00513	CcSEcCtD
Nabilone—Mental disability—Epirubicin—bone cancer	0.00455	0.0051	CcSEcCtD
Nabilone—Dry eye—Doxorubicin—bone cancer	0.00448	0.00502	CcSEcCtD
Nabilone—Coma—Doxorubicin—bone cancer	0.00443	0.00497	CcSEcCtD
Nabilone—Photosensitivity—Epirubicin—bone cancer	0.00433	0.00486	CcSEcCtD
Nabilone—Visual disturbance—Methotrexate—bone cancer	0.00429	0.00481	CcSEcCtD
Nabilone—Mental disability—Doxorubicin—bone cancer	0.00421	0.00472	CcSEcCtD
Nabilone—Vision blurred—Cisplatin—bone cancer	0.0042	0.00471	CcSEcCtD
Nabilone—Tremor—Cisplatin—bone cancer	0.00418	0.00468	CcSEcCtD
Nabilone—Cerebrovascular accident—Methotrexate—bone cancer	0.00415	0.00465	CcSEcCtD
Nabilone—Ill-defined disorder—Cisplatin—bone cancer	0.00414	0.00464	CcSEcCtD
Nabilone—Anaemia—Cisplatin—bone cancer	0.00412	0.00462	CcSEcCtD
Nabilone—Hot flush—Epirubicin—bone cancer	0.00407	0.00456	CcSEcCtD
Nabilone—Increased appetite—Epirubicin—bone cancer	0.00405	0.00454	CcSEcCtD
Nabilone—Menopausal symptoms—Epirubicin—bone cancer	0.00403	0.00452	CcSEcCtD
Nabilone—Malaise—Cisplatin—bone cancer	0.00402	0.00451	CcSEcCtD
Nabilone—Photosensitivity—Doxorubicin—bone cancer	0.00401	0.00449	CcSEcCtD
Nabilone—Leukopenia—Cisplatin—bone cancer	0.00399	0.00448	CcSEcCtD
Nabilone—Cerebrovascular accident—Epirubicin—bone cancer	0.00388	0.00435	CcSEcCtD
Nabilone—Irritability—Methotrexate—bone cancer	0.00388	0.00435	CcSEcCtD
Nabilone—Convulsion—Cisplatin—bone cancer	0.00386	0.00433	CcSEcCtD
Nabilone—Mood swings—Methotrexate—bone cancer	0.00385	0.00432	CcSEcCtD
Nabilone—Ataxia—Methotrexate—bone cancer	0.00382	0.00428	CcSEcCtD
Nabilone—Myalgia—Cisplatin—bone cancer	0.0038	0.00426	CcSEcCtD
Nabilone—Anxiety—Cisplatin—bone cancer	0.00378	0.00424	CcSEcCtD
Nabilone—Hot flush—Doxorubicin—bone cancer	0.00376	0.00422	CcSEcCtD
Nabilone—Discomfort—Cisplatin—bone cancer	0.00375	0.00421	CcSEcCtD
Nabilone—Increased appetite—Doxorubicin—bone cancer	0.00375	0.0042	CcSEcCtD
Nabilone—Affect lability—Epirubicin—bone cancer	0.00374	0.0042	CcSEcCtD
Nabilone—Menopausal symptoms—Doxorubicin—bone cancer	0.00373	0.00418	CcSEcCtD
Nabilone—Face oedema—Epirubicin—bone cancer	0.00367	0.00412	CcSEcCtD
Nabilone—Infection—Cisplatin—bone cancer	0.00362	0.00405	CcSEcCtD
Nabilone—Mood swings—Epirubicin—bone cancer	0.0036	0.00404	CcSEcCtD
Nabilone—Cerebrovascular accident—Doxorubicin—bone cancer	0.00359	0.00403	CcSEcCtD
Nabilone—Ataxia—Epirubicin—bone cancer	0.00358	0.00401	CcSEcCtD
Nabilone—CNR1—GPCRs, Other—SMO—bone cancer	0.00355	0.0598	CbGpPWpGaD
Nabilone—Tachycardia—Cisplatin—bone cancer	0.00355	0.00398	CcSEcCtD
Nabilone—Hyperhidrosis—Cisplatin—bone cancer	0.00352	0.00394	CcSEcCtD
Nabilone—Orthostatic hypotension—Epirubicin—bone cancer	0.00347	0.00389	CcSEcCtD
Nabilone—CNR2—G alpha (i) signalling events—GRM4—bone cancer	0.00347	0.0584	CbGpPWpGaD
Nabilone—CNR2—G alpha (i) signalling events—RGS1—bone cancer	0.00347	0.0584	CbGpPWpGaD
Nabilone—Anorexia—Cisplatin—bone cancer	0.00347	0.00389	CcSEcCtD
Nabilone—Affect lability—Doxorubicin—bone cancer	0.00346	0.00388	CcSEcCtD
Nabilone—Hypotension—Cisplatin—bone cancer	0.0034	0.00381	CcSEcCtD
Nabilone—Face oedema—Doxorubicin—bone cancer	0.0034	0.00381	CcSEcCtD
Nabilone—Gastritis—Epirubicin—bone cancer	0.00337	0.00377	CcSEcCtD
Nabilone—Mood swings—Doxorubicin—bone cancer	0.00333	0.00374	CcSEcCtD
Nabilone—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00332	0.00372	CcSEcCtD
Nabilone—Ataxia—Doxorubicin—bone cancer	0.00331	0.00371	CcSEcCtD
Nabilone—Paraesthesia—Cisplatin—bone cancer	0.00327	0.00366	CcSEcCtD
Nabilone—Dyspnoea—Cisplatin—bone cancer	0.00324	0.00364	CcSEcCtD
Nabilone—Orthostatic hypotension—Doxorubicin—bone cancer	0.00321	0.0036	CcSEcCtD
Nabilone—Photosensitivity reaction—Methotrexate—bone cancer	0.00321	0.00359	CcSEcCtD
Nabilone—Decreased appetite—Cisplatin—bone cancer	0.00316	0.00355	CcSEcCtD
Nabilone—Drowsiness—Methotrexate—bone cancer	0.00313	0.00351	CcSEcCtD
Nabilone—Depression—Methotrexate—bone cancer	0.00312	0.0035	CcSEcCtD
Nabilone—Gastritis—Doxorubicin—bone cancer	0.00311	0.00349	CcSEcCtD
Nabilone—Pain—Cisplatin—bone cancer	0.00311	0.00349	CcSEcCtD
Nabilone—Stomatitis—Methotrexate—bone cancer	0.00305	0.00342	CcSEcCtD
Nabilone—Pollakiuria—Epirubicin—bone cancer	0.00304	0.0034	CcSEcCtD
Nabilone—Photosensitivity reaction—Epirubicin—bone cancer	0.003	0.00336	CcSEcCtD
Nabilone—Feeling abnormal—Cisplatin—bone cancer	0.003	0.00336	CcSEcCtD
Nabilone—Epistaxis—Methotrexate—bone cancer	0.00295	0.00331	CcSEcCtD
Nabilone—Drowsiness—Epirubicin—bone cancer	0.00293	0.00329	CcSEcCtD
Nabilone—Body temperature increased—Cisplatin—bone cancer	0.00288	0.00323	CcSEcCtD
Nabilone—Stomatitis—Epirubicin—bone cancer	0.00286	0.0032	CcSEcCtD
Nabilone—Pollakiuria—Doxorubicin—bone cancer	0.00281	0.00315	CcSEcCtD
Nabilone—Pharyngitis—Methotrexate—bone cancer	0.00279	0.00313	CcSEcCtD
Nabilone—Photosensitivity reaction—Doxorubicin—bone cancer	0.00278	0.00311	CcSEcCtD
Nabilone—Epistaxis—Epirubicin—bone cancer	0.00276	0.0031	CcSEcCtD
Nabilone—CNR1—G alpha (i) signalling events—GRM4—bone cancer	0.00272	0.0458	CbGpPWpGaD
Nabilone—CNR1—G alpha (i) signalling events—RGS1—bone cancer	0.00272	0.0458	CbGpPWpGaD
Nabilone—Drowsiness—Doxorubicin—bone cancer	0.00271	0.00304	CcSEcCtD
Nabilone—Visual impairment—Methotrexate—bone cancer	0.00271	0.00304	CcSEcCtD
Nabilone—Hypersensitivity—Cisplatin—bone cancer	0.00268	0.00301	CcSEcCtD
Nabilone—Stomatitis—Doxorubicin—bone cancer	0.00264	0.00296	CcSEcCtD
Nabilone—Eye disorder—Methotrexate—bone cancer	0.00263	0.00295	CcSEcCtD
Nabilone—Tinnitus—Methotrexate—bone cancer	0.00262	0.00294	CcSEcCtD
Nabilone—Hypoaesthesia—Epirubicin—bone cancer	0.00262	0.00293	CcSEcCtD
Nabilone—Asthenia—Cisplatin—bone cancer	0.00261	0.00293	CcSEcCtD
Nabilone—Pharyngitis—Epirubicin—bone cancer	0.00261	0.00293	CcSEcCtD
Nabilone—CNR1—BDNF signaling pathway—EIF2S1—bone cancer	0.00258	0.0434	CbGpPWpGaD
Nabilone—Epistaxis—Doxorubicin—bone cancer	0.00256	0.00287	CcSEcCtD
Nabilone—Visual impairment—Epirubicin—bone cancer	0.00254	0.00284	CcSEcCtD
Nabilone—Chills—Methotrexate—bone cancer	0.00252	0.00283	CcSEcCtD
Nabilone—Diarrhoea—Cisplatin—bone cancer	0.00249	0.00279	CcSEcCtD
Nabilone—Eye disorder—Epirubicin—bone cancer	0.00246	0.00276	CcSEcCtD
Nabilone—Tinnitus—Epirubicin—bone cancer	0.00245	0.00275	CcSEcCtD
Nabilone—Flushing—Epirubicin—bone cancer	0.00244	0.00274	CcSEcCtD
Nabilone—Hypoaesthesia—Doxorubicin—bone cancer	0.00242	0.00272	CcSEcCtD
Nabilone—Pharyngitis—Doxorubicin—bone cancer	0.00242	0.00271	CcSEcCtD
Nabilone—Back pain—Methotrexate—bone cancer	0.00237	0.00265	CcSEcCtD
Nabilone—Chills—Epirubicin—bone cancer	0.00236	0.00265	CcSEcCtD
Nabilone—Arrhythmia—Epirubicin—bone cancer	0.00235	0.00263	CcSEcCtD
Nabilone—Visual impairment—Doxorubicin—bone cancer	0.00235	0.00263	CcSEcCtD
Nabilone—Vomiting—Cisplatin—bone cancer	0.00231	0.00259	CcSEcCtD
Nabilone—Vision blurred—Methotrexate—bone cancer	0.00231	0.00259	CcSEcCtD
Nabilone—Rash—Cisplatin—bone cancer	0.00229	0.00257	CcSEcCtD
Nabilone—Dermatitis—Cisplatin—bone cancer	0.00229	0.00257	CcSEcCtD
Nabilone—Eye disorder—Doxorubicin—bone cancer	0.00227	0.00255	CcSEcCtD
Nabilone—Ill-defined disorder—Methotrexate—bone cancer	0.00227	0.00255	CcSEcCtD
Nabilone—Tinnitus—Doxorubicin—bone cancer	0.00227	0.00254	CcSEcCtD
Nabilone—Anaemia—Methotrexate—bone cancer	0.00226	0.00254	CcSEcCtD
Nabilone—Flushing—Doxorubicin—bone cancer	0.00226	0.00253	CcSEcCtD
Nabilone—Tension—Epirubicin—bone cancer	0.00225	0.00252	CcSEcCtD
Nabilone—Nervousness—Epirubicin—bone cancer	0.00222	0.00249	CcSEcCtD
Nabilone—Back pain—Epirubicin—bone cancer	0.00222	0.00248	CcSEcCtD
Nabilone—Malaise—Methotrexate—bone cancer	0.00221	0.00247	CcSEcCtD
Nabilone—Vertigo—Methotrexate—bone cancer	0.0022	0.00246	CcSEcCtD
Nabilone—Leukopenia—Methotrexate—bone cancer	0.00219	0.00246	CcSEcCtD
Nabilone—Chills—Doxorubicin—bone cancer	0.00218	0.00245	CcSEcCtD
Nabilone—Arrhythmia—Doxorubicin—bone cancer	0.00217	0.00244	CcSEcCtD
Nabilone—Nausea—Cisplatin—bone cancer	0.00216	0.00242	CcSEcCtD
Nabilone—Vision blurred—Epirubicin—bone cancer	0.00216	0.00242	CcSEcCtD
Nabilone—Cough—Methotrexate—bone cancer	0.00214	0.00239	CcSEcCtD
Nabilone—Ill-defined disorder—Epirubicin—bone cancer	0.00212	0.00238	CcSEcCtD
Nabilone—Convulsion—Methotrexate—bone cancer	0.00212	0.00238	CcSEcCtD
Nabilone—Anaemia—Epirubicin—bone cancer	0.00212	0.00237	CcSEcCtD
Nabilone—Agitation—Epirubicin—bone cancer	0.0021	0.00236	CcSEcCtD
Nabilone—CNR2—GPCR ligand binding—GRM4—bone cancer	0.0021	0.0353	CbGpPWpGaD
Nabilone—Arthralgia—Methotrexate—bone cancer	0.00208	0.00234	CcSEcCtD
Nabilone—Chest pain—Methotrexate—bone cancer	0.00208	0.00234	CcSEcCtD
Nabilone—Myalgia—Methotrexate—bone cancer	0.00208	0.00234	CcSEcCtD
Nabilone—Tension—Doxorubicin—bone cancer	0.00208	0.00233	CcSEcCtD
Nabilone—Malaise—Epirubicin—bone cancer	0.00207	0.00232	CcSEcCtD
Nabilone—Discomfort—Methotrexate—bone cancer	0.00206	0.00231	CcSEcCtD
Nabilone—Nervousness—Doxorubicin—bone cancer	0.00206	0.00231	CcSEcCtD
Nabilone—Vertigo—Epirubicin—bone cancer	0.00206	0.00231	CcSEcCtD
Nabilone—Syncope—Epirubicin—bone cancer	0.00205	0.0023	CcSEcCtD
Nabilone—Leukopenia—Epirubicin—bone cancer	0.00205	0.0023	CcSEcCtD
Nabilone—Back pain—Doxorubicin—bone cancer	0.00205	0.0023	CcSEcCtD
Nabilone—Palpitations—Epirubicin—bone cancer	0.00202	0.00227	CcSEcCtD
Nabilone—Confusional state—Methotrexate—bone cancer	0.00201	0.00226	CcSEcCtD
Nabilone—Loss of consciousness—Epirubicin—bone cancer	0.00201	0.00226	CcSEcCtD
Nabilone—Cough—Epirubicin—bone cancer	0.002	0.00224	CcSEcCtD
Nabilone—Vision blurred—Doxorubicin—bone cancer	0.002	0.00224	CcSEcCtD
Nabilone—Convulsion—Epirubicin—bone cancer	0.00198	0.00222	CcSEcCtD
Nabilone—Infection—Methotrexate—bone cancer	0.00198	0.00222	CcSEcCtD
Nabilone—Hypertension—Epirubicin—bone cancer	0.00198	0.00222	CcSEcCtD
Nabilone—Ill-defined disorder—Doxorubicin—bone cancer	0.00197	0.0022	CcSEcCtD
Nabilone—Anaemia—Doxorubicin—bone cancer	0.00196	0.0022	CcSEcCtD
Nabilone—Chest pain—Epirubicin—bone cancer	0.00195	0.00219	CcSEcCtD
Nabilone—Myalgia—Epirubicin—bone cancer	0.00195	0.00219	CcSEcCtD
Nabilone—Arthralgia—Epirubicin—bone cancer	0.00195	0.00219	CcSEcCtD
Nabilone—Agitation—Doxorubicin—bone cancer	0.00195	0.00218	CcSEcCtD
Nabilone—Anxiety—Epirubicin—bone cancer	0.00194	0.00218	CcSEcCtD
Nabilone—Hyperhidrosis—Methotrexate—bone cancer	0.00193	0.00216	CcSEcCtD
Nabilone—Discomfort—Epirubicin—bone cancer	0.00193	0.00216	CcSEcCtD
Nabilone—Malaise—Doxorubicin—bone cancer	0.00191	0.00214	CcSEcCtD
Nabilone—Dry mouth—Epirubicin—bone cancer	0.00191	0.00214	CcSEcCtD
Nabilone—Vertigo—Doxorubicin—bone cancer	0.0019	0.00213	CcSEcCtD
Nabilone—Anorexia—Methotrexate—bone cancer	0.0019	0.00213	CcSEcCtD
Nabilone—Syncope—Doxorubicin—bone cancer	0.0019	0.00213	CcSEcCtD
Nabilone—Leukopenia—Doxorubicin—bone cancer	0.0019	0.00213	CcSEcCtD
Nabilone—Confusional state—Epirubicin—bone cancer	0.00188	0.00211	CcSEcCtD
Nabilone—Palpitations—Doxorubicin—bone cancer	0.00187	0.0021	CcSEcCtD
Nabilone—Hypotension—Methotrexate—bone cancer	0.00187	0.00209	CcSEcCtD
Nabilone—Loss of consciousness—Doxorubicin—bone cancer	0.00186	0.00209	CcSEcCtD
Nabilone—Infection—Epirubicin—bone cancer	0.00186	0.00208	CcSEcCtD
Nabilone—Cough—Doxorubicin—bone cancer	0.00185	0.00207	CcSEcCtD
Nabilone—Shock—Epirubicin—bone cancer	0.00184	0.00206	CcSEcCtD
Nabilone—Convulsion—Doxorubicin—bone cancer	0.00184	0.00206	CcSEcCtD
Nabilone—Hypertension—Doxorubicin—bone cancer	0.00183	0.00205	CcSEcCtD
Nabilone—Tachycardia—Epirubicin—bone cancer	0.00182	0.00204	CcSEcCtD
Nabilone—CNR2—GPCR ligand binding—GRM1—bone cancer	0.00182	0.0306	CbGpPWpGaD
Nabilone—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00182	0.00204	CcSEcCtD
Nabilone—Hyperhidrosis—Epirubicin—bone cancer	0.00181	0.00203	CcSEcCtD
Nabilone—Insomnia—Methotrexate—bone cancer	0.00181	0.00203	CcSEcCtD
Nabilone—Myalgia—Doxorubicin—bone cancer	0.0018	0.00202	CcSEcCtD
Nabilone—Arthralgia—Doxorubicin—bone cancer	0.0018	0.00202	CcSEcCtD
Nabilone—Chest pain—Doxorubicin—bone cancer	0.0018	0.00202	CcSEcCtD
Nabilone—Anxiety—Doxorubicin—bone cancer	0.0018	0.00202	CcSEcCtD
Nabilone—Paraesthesia—Methotrexate—bone cancer	0.00179	0.00201	CcSEcCtD
Nabilone—Discomfort—Doxorubicin—bone cancer	0.00178	0.002	CcSEcCtD
Nabilone—Anorexia—Epirubicin—bone cancer	0.00178	0.002	CcSEcCtD
Nabilone—Dyspnoea—Methotrexate—bone cancer	0.00178	0.002	CcSEcCtD
Nabilone—Somnolence—Methotrexate—bone cancer	0.00178	0.00199	CcSEcCtD
Nabilone—Dry mouth—Doxorubicin—bone cancer	0.00176	0.00198	CcSEcCtD
Nabilone—Dyspepsia—Methotrexate—bone cancer	0.00176	0.00197	CcSEcCtD
Nabilone—Hypotension—Epirubicin—bone cancer	0.00175	0.00196	CcSEcCtD
Nabilone—Confusional state—Doxorubicin—bone cancer	0.00174	0.00195	CcSEcCtD
Nabilone—Decreased appetite—Methotrexate—bone cancer	0.00174	0.00195	CcSEcCtD
Nabilone—Fatigue—Methotrexate—bone cancer	0.00172	0.00193	CcSEcCtD
Nabilone—Infection—Doxorubicin—bone cancer	0.00172	0.00193	CcSEcCtD
Nabilone—Pain—Methotrexate—bone cancer	0.00171	0.00191	CcSEcCtD
Nabilone—Musculoskeletal discomfort—Epirubicin—bone cancer	0.0017	0.00191	CcSEcCtD
Nabilone—Shock—Doxorubicin—bone cancer	0.0017	0.00191	CcSEcCtD
Nabilone—Insomnia—Epirubicin—bone cancer	0.00169	0.0019	CcSEcCtD
Nabilone—Tachycardia—Doxorubicin—bone cancer	0.00169	0.00189	CcSEcCtD
Nabilone—Paraesthesia—Epirubicin—bone cancer	0.00168	0.00188	CcSEcCtD
Nabilone—Hyperhidrosis—Doxorubicin—bone cancer	0.00167	0.00187	CcSEcCtD
Nabilone—Dyspnoea—Epirubicin—bone cancer	0.00167	0.00187	CcSEcCtD
Nabilone—Somnolence—Epirubicin—bone cancer	0.00166	0.00186	CcSEcCtD
Nabilone—CNR1—GPCR ligand binding—GRM4—bone cancer	0.00165	0.0277	CbGpPWpGaD
Nabilone—Anorexia—Doxorubicin—bone cancer	0.00165	0.00185	CcSEcCtD
Nabilone—Feeling abnormal—Methotrexate—bone cancer	0.00165	0.00185	CcSEcCtD
Nabilone—Dyspepsia—Epirubicin—bone cancer	0.00165	0.00184	CcSEcCtD
Nabilone—Gastrointestinal pain—Methotrexate—bone cancer	0.00163	0.00183	CcSEcCtD
Nabilone—Decreased appetite—Epirubicin—bone cancer	0.00162	0.00182	CcSEcCtD
Nabilone—Hypotension—Doxorubicin—bone cancer	0.00162	0.00181	CcSEcCtD
Nabilone—Fatigue—Epirubicin—bone cancer	0.00161	0.00181	CcSEcCtD
Nabilone—Pain—Epirubicin—bone cancer	0.0016	0.00179	CcSEcCtD
Nabilone—Constipation—Epirubicin—bone cancer	0.0016	0.00179	CcSEcCtD
Nabilone—Abdominal pain—Methotrexate—bone cancer	0.00158	0.00177	CcSEcCtD
Nabilone—Body temperature increased—Methotrexate—bone cancer	0.00158	0.00177	CcSEcCtD
Nabilone—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.00158	0.00177	CcSEcCtD
Nabilone—Insomnia—Doxorubicin—bone cancer	0.00156	0.00175	CcSEcCtD
Nabilone—Paraesthesia—Doxorubicin—bone cancer	0.00155	0.00174	CcSEcCtD
Nabilone—Dyspnoea—Doxorubicin—bone cancer	0.00154	0.00173	CcSEcCtD
Nabilone—Feeling abnormal—Epirubicin—bone cancer	0.00154	0.00173	CcSEcCtD
Nabilone—Somnolence—Doxorubicin—bone cancer	0.00154	0.00172	CcSEcCtD
Nabilone—Gastrointestinal pain—Epirubicin—bone cancer	0.00153	0.00171	CcSEcCtD
Nabilone—Dyspepsia—Doxorubicin—bone cancer	0.00152	0.00171	CcSEcCtD
Nabilone—Decreased appetite—Doxorubicin—bone cancer	0.0015	0.00169	CcSEcCtD
Nabilone—Fatigue—Doxorubicin—bone cancer	0.00149	0.00167	CcSEcCtD
Nabilone—Pain—Doxorubicin—bone cancer	0.00148	0.00166	CcSEcCtD
Nabilone—Constipation—Doxorubicin—bone cancer	0.00148	0.00166	CcSEcCtD
Nabilone—Abdominal pain—Epirubicin—bone cancer	0.00148	0.00166	CcSEcCtD
Nabilone—Body temperature increased—Epirubicin—bone cancer	0.00148	0.00166	CcSEcCtD
Nabilone—Hypersensitivity—Methotrexate—bone cancer	0.00147	0.00165	CcSEcCtD
Nabilone—Asthenia—Methotrexate—bone cancer	0.00143	0.00161	CcSEcCtD
Nabilone—CNR1—GPCR ligand binding—GRM1—bone cancer	0.00143	0.024	CbGpPWpGaD
Nabilone—Feeling abnormal—Doxorubicin—bone cancer	0.00143	0.0016	CcSEcCtD
Nabilone—Gastrointestinal pain—Doxorubicin—bone cancer	0.00141	0.00159	CcSEcCtD
Nabilone—Pruritus—Methotrexate—bone cancer	0.00141	0.00158	CcSEcCtD
Nabilone—Hypersensitivity—Epirubicin—bone cancer	0.00138	0.00154	CcSEcCtD
Nabilone—Abdominal pain—Doxorubicin—bone cancer	0.00137	0.00153	CcSEcCtD
Nabilone—Body temperature increased—Doxorubicin—bone cancer	0.00137	0.00153	CcSEcCtD
Nabilone—Diarrhoea—Methotrexate—bone cancer	0.00137	0.00153	CcSEcCtD
Nabilone—Asthenia—Epirubicin—bone cancer	0.00134	0.0015	CcSEcCtD
Nabilone—Pruritus—Epirubicin—bone cancer	0.00132	0.00148	CcSEcCtD
Nabilone—Dizziness—Methotrexate—bone cancer	0.00132	0.00148	CcSEcCtD
Nabilone—CNR2—GPCR ligand binding—SMO—bone cancer	0.00128	0.0216	CbGpPWpGaD
Nabilone—Diarrhoea—Epirubicin—bone cancer	0.00128	0.00143	CcSEcCtD
Nabilone—Hypersensitivity—Doxorubicin—bone cancer	0.00127	0.00143	CcSEcCtD
Nabilone—Vomiting—Methotrexate—bone cancer	0.00127	0.00142	CcSEcCtD
Nabilone—Rash—Methotrexate—bone cancer	0.00126	0.00141	CcSEcCtD
Nabilone—Dermatitis—Methotrexate—bone cancer	0.00126	0.00141	CcSEcCtD
Nabilone—Headache—Methotrexate—bone cancer	0.00125	0.0014	CcSEcCtD
Nabilone—Asthenia—Doxorubicin—bone cancer	0.00124	0.00139	CcSEcCtD
Nabilone—Dizziness—Epirubicin—bone cancer	0.00124	0.00139	CcSEcCtD
Nabilone—Pruritus—Doxorubicin—bone cancer	0.00122	0.00137	CcSEcCtD
Nabilone—Vomiting—Epirubicin—bone cancer	0.00119	0.00133	CcSEcCtD
Nabilone—CNR2—GPCR downstream signaling—RGS1—bone cancer	0.00119	0.02	CbGpPWpGaD
Nabilone—CNR2—GPCR downstream signaling—GRM4—bone cancer	0.00119	0.02	CbGpPWpGaD
Nabilone—Nausea—Methotrexate—bone cancer	0.00119	0.00133	CcSEcCtD
Nabilone—Diarrhoea—Doxorubicin—bone cancer	0.00118	0.00133	CcSEcCtD
Nabilone—Rash—Epirubicin—bone cancer	0.00118	0.00132	CcSEcCtD
Nabilone—Dermatitis—Epirubicin—bone cancer	0.00118	0.00132	CcSEcCtD
Nabilone—Headache—Epirubicin—bone cancer	0.00117	0.00131	CcSEcCtD
Nabilone—Dizziness—Doxorubicin—bone cancer	0.00114	0.00128	CcSEcCtD
Nabilone—Nausea—Epirubicin—bone cancer	0.00111	0.00124	CcSEcCtD
Nabilone—Vomiting—Doxorubicin—bone cancer	0.0011	0.00123	CcSEcCtD
Nabilone—Rash—Doxorubicin—bone cancer	0.00109	0.00122	CcSEcCtD
Nabilone—Dermatitis—Doxorubicin—bone cancer	0.00109	0.00122	CcSEcCtD
Nabilone—Headache—Doxorubicin—bone cancer	0.00108	0.00121	CcSEcCtD
Nabilone—CNR2—Signaling by GPCR—GRM4—bone cancer	0.00108	0.0181	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—RGS1—bone cancer	0.00108	0.0181	CbGpPWpGaD
Nabilone—CNR2—GPCR downstream signaling—GRM1—bone cancer	0.00103	0.0173	CbGpPWpGaD
Nabilone—Nausea—Doxorubicin—bone cancer	0.00103	0.00115	CcSEcCtD
Nabilone—CNR1—GPCR ligand binding—SMO—bone cancer	0.00101	0.0169	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—GRM1—bone cancer	0.000935	0.0157	CbGpPWpGaD
Nabilone—CNR1—GPCR downstream signaling—GRM4—bone cancer	0.000932	0.0157	CbGpPWpGaD
Nabilone—CNR1—GPCR downstream signaling—RGS1—bone cancer	0.000932	0.0157	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—GRM4—bone cancer	0.000847	0.0142	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—RGS1—bone cancer	0.000847	0.0142	CbGpPWpGaD
Nabilone—CNR1—BDNF signaling pathway—JUN—bone cancer	0.000816	0.0137	CbGpPWpGaD
Nabilone—CNR1—GPCR downstream signaling—GRM1—bone cancer	0.000808	0.0136	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—GRM1—bone cancer	0.000734	0.0123	CbGpPWpGaD
Nabilone—CNR2—GPCR downstream signaling—GNA11—bone cancer	0.000664	0.0112	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—SMO—bone cancer	0.000659	0.0111	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—RGS1—bone cancer	0.000637	0.0107	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—GRM4—bone cancer	0.000637	0.0107	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—GNA11—bone cancer	0.000603	0.0101	CbGpPWpGaD
Nabilone—CNR2—GPCR downstream signaling—IL3—bone cancer	0.000602	0.0101	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—GRM1—bone cancer	0.000553	0.00929	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—IL3—bone cancer	0.000546	0.00919	CbGpPWpGaD
Nabilone—CNR1—GPCR downstream signaling—GNA11—bone cancer	0.000521	0.00876	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—SMO—bone cancer	0.000517	0.00869	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—GRM4—bone cancer	0.0005	0.00841	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—RGS1—bone cancer	0.0005	0.00841	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—GNA11—bone cancer	0.000473	0.00795	CbGpPWpGaD
Nabilone—CNR1—GPCR downstream signaling—IL3—bone cancer	0.000472	0.00794	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—GRM1—bone cancer	0.000434	0.00729	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—IL3—bone cancer	0.000429	0.00721	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—SMO—bone cancer	0.000389	0.00654	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—GNA11—bone cancer	0.000356	0.00599	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—ATF1—bone cancer	0.000331	0.00556	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—IL3—bone cancer	0.000323	0.00543	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—SMO—bone cancer	0.000305	0.00514	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—GNA11—bone cancer	0.000279	0.0047	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—TGFBR2—bone cancer	0.000276	0.00464	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—IGF1R—bone cancer	0.00026	0.00437	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—ATF1—bone cancer	0.00026	0.00437	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—IL3—bone cancer	0.000253	0.00426	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—TGFBR2—bone cancer	0.000217	0.00364	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—IGF1R—bone cancer	0.000204	0.00343	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—KIT—bone cancer	0.000188	0.00317	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—BRAF—bone cancer	0.000177	0.00298	CbGpPWpGaD
Nabilone—CNR2—Signaling by GPCR—EGFR—bone cancer	0.000172	0.00289	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—MDM2—bone cancer	0.000148	0.00249	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—KIT—bone cancer	0.000148	0.00249	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—BRAF—bone cancer	0.000139	0.00234	CbGpPWpGaD
Nabilone—CNR1—Signaling by GPCR—EGFR—bone cancer	0.000135	0.00226	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—JUN—bone cancer	0.000129	0.00217	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—MMP9—bone cancer	0.000125	0.00211	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—MDM2—bone cancer	0.000116	0.00196	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—EGFR—bone cancer	0.000101	0.0017	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—JUN—bone cancer	0.000101	0.0017	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—MMP9—bone cancer	9.85e-05	0.00166	CbGpPWpGaD
Nabilone—CNR2—Signaling Pathways—TP53—bone cancer	8.51e-05	0.00143	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—EGFR—bone cancer	7.96e-05	0.00134	CbGpPWpGaD
Nabilone—CNR1—Signaling Pathways—TP53—bone cancer	6.68e-05	0.00112	CbGpPWpGaD
